Baxter
(NYSE: BAX)
announced today that it launched the PerClot absorbable hemostatic powder in the U.S.
PerClot, a passive, absorbable hemostatic powder, received FDA approval in May. Artivion developed the powder and transferred full ownership to Baxter as part of a sale agreement struck in July 2021.
Artivion designed PerClot to control mild bleeding in specific surgical procedures. It comes ready to use for patients with intact coagulation. The powder’s granules have a molecular structure that rapidly absorbs water to form a gelled adhesive matrix. This provides a mechanical barrier against further bleeding. It also results in the accumulation of platelets, red blood cells and coagulation proteins.
“PerClot is a strong complement to Baxter’s leading hemostat portfolio,” said Steve Wallace, president, Advanced Surgery at Baxter. “The launch of PerClot in the U.S. allows us to provide surgeons with a full range of active and passive hemostatic products for bleeding control, helping to optimize care for their patients.”
Alongside the PerClot launch, Baxter plans to work with customers representing leading hospitals to add the powder to their standard of care.
The powder enhances clinicians’ ability to optimize patient care by addressing a broader range of intraoperative bleeding, Baxter says. It could help to reduce blood transfusions and major complications while lowering the total cost of care.
Baxter said it continues to expand the global commercial presence of PerClot since it acquired the powder. To date, PerClot has sales in more than 35 countries worldwide.